Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.

Qin, Wenhui; Yang, Jun; Deng, Chao; Ruan, Qinjuan; Duan, Kai

Qin, Wenhui; Yang, Jun; Deng, Chao; Ruan, Qinjuan; Duan, Kai.

Afiliación

Qin W; Department of Endocrinology and Metabolism, Jingshan Union Hospital of Huazhong University of Science and Technology, Jingmen, China.
Yang J; Department of Endocrinology and Metabolism, Jingshan Union Hospital of Huazhong University of Science and Technology, Jingmen, China.
Deng C; Department of Pharmacy, Jingshan Union Hospital of Huazhong University of Science and Technology, Jingmen, China.
Ruan Q; Department of Pharmacy, Jingshan Union Hospital of Huazhong University of Science and Technology, Jingmen, China.
Duan K; Department of Nephrology, Jingshan Union Hospital of Huazhong University of Science and Technology, Jingmen, China.

Diabetes Obes Metab ; 26(3): 911-923, 2024 Mar.

Article en En | MEDLINE | ID: mdl-38016699

Asunto(s)

Diabetes Mellitus; Sobrepeso; Adulto; Humanos; Sobrepeso/complicaciones; Sobrepeso/tratamiento farmacológico; Sobrepeso/inducido químicamente; Hipoglucemiantes/efectos adversos; Obesidad/complicaciones; Obesidad/tratamiento farmacológico; Obesidad/inducido químicamente; Diabetes Mellitus/tratamiento farmacológico; Pérdida de Peso; Péptidos Similares al Glucagón/efectos adversos

Palabras clave

meta-analysis; obesity; semaglutide; systematic review; weight loss; without diabetes

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus / Sobrepeso Tipo de estudio: Systematic_reviews Límite: Adult / Humans Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google